Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31384232 | 0.91 | SLC6A5 (0.50) | SLC6A5KMT2APOLBERAP2LNPEP | |
| SCHEMBL31467198 | 0.86 | SLC6A5 (0.56) | SLC6A5KMT2APOLBNOD1NMT2 | |
| SCHEMBL28698069 | 0.82 | SLC6A5 (0.62) | SLC6A5KMT2ANOD1ERAP2LNPEP | |
| SCHEMBL18796577 | 0.81 | SLC6A5 (0.64) | SLC6A5KMT2ANOD1ERAP2LNPEP | |
| SCHEMBL8015739 | 0.81 | SLC6A5 (0.64) | SLC6A5KMT2ANOD1ERAP2LNPEP | |
| SCHEMBL18796595 | 0.81 | SLC6A5 (0.64) | SLC6A5KMT2ANOD1ERAP2LNPEP | |
| SCHEMBL8620977 | 0.81 | SLC6A5 (0.64) | SLC6A5KMT2ANOD1ERAP2LNPEP | |
| SCHEMBL8015737 | 0.81 | SLC6A5 (0.64) | SLC6A5KMT2ANOD1ERAP2LNPEP | |
| SCHEMBL3174603 | 0.81 | SLC6A5 (0.64) | SLC6A5KMT2ANOD1ERAP2LNPEP | |
| SCHEMBL28476514 | 0.81 | SLC6A5 (0.64) | SLC6A5KMT2ANOD1ERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090214598-A1 | Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease | ELI LILLY AND COMPANY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214598-A1 | Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease | CD4, TLR2, CD69 | SLC6A5 1316/4885KMT2A 2671/4885POLB 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.